US Bancorp’s iRadimed IRMD Stock Holding History

US Bancorp’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.6K	Buy	645 +123	+24%	+$11.2K	﹤0.01%	2697
2026 Q1	$50.2K	Buy	522 +16	+3%	+$1.6K	﹤0.01%	2706
2025 Q4	$49.2K	Sell	506 -30	-6%	-$2.57K	﹤0.01%	2707
2025 Q3	$38.1K	Buy	536 +1	+0.2%	+$67	﹤0.01%	2794
2025 Q2	$32K	Sell	535 -901	-63%	-$49.4K	﹤0.01%	2983
2025 Q1	$75.4K	Buy	1,436 +819	+133%	+$46K	﹤0.01%	2533
2024 Q4	$34K	Buy	617 +510	+477%	+$26.8K	﹤0.01%	2925
2024 Q3	$5.39K	Sell	107 -11	-9%	-$507	﹤0.01%	3550
2024 Q2	$5.19K	Sell	118 -40	-25%	-$1.7K	﹤0.01%	3502
2024 Q1	$6.95K	Buy	+158	New	+$6.98K	﹤0.01%	3441
2022 Q1	–	Sell	-400	Closed	-$18K	–	4129
2021 Q4	$18K	Hold	400	–	–	﹤0.01%	3163
2021 Q3	$13K	Buy	+400	New	+$13.6K	﹤0.01%	3328
2017 Q1	–	Sell	-1,620	Closed	-$18K	–	3589
2016 Q4	$18K	Buy	+1,620	New	+$17.4K	﹤0.01%	2875

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's IRMD Position: Q2 2026 in Review

US Bancorp increased its iRadimed (IRMD) stake by 24% in Q2 2026, buying an estimated $11.2K and bringing the position to 645 shares worth $61.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

US Bancorp first reported a position in IRMD in Q4 2016 and has held it in 13 quarters since. The position peaked at $75.4K in Q1 2025. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

US Bancorp held 645 shares of iRadimed worth $61.6K as of Q2 2026.
US Bancorp bought 123 iRadimed shares in Q2 2026, an estimated $11.2K.
iRadimed made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2697 holding.
US Bancorp first reported a position in iRadimed in Q4 2016 and has held it in 13 quarters since.
US Bancorp's iRadimed position peaked at $75.4K in Q1 2025.
213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.